These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1082 related articles for article (PubMed ID: 36287379)

  • 1. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
    Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
    Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
    Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
    BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
    Dubberke ER; Lee CH; Orenstein R; Khanna S; Hecht G; Gerding DN
    Clin Infect Dis; 2018 Sep; 67(8):1198-1204. PubMed ID: 29617739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SER-109 (VOWST
    Blair HA
    Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
    Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
    J Clin Gastroenterol; 2024 Sep; 58(8):818-824. PubMed ID: 38019088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
    Orenstein R
    Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
    Chopra T
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent
    Tillotson G; Archbald-Pannone L; Johnson S; Ng S; Ando M; Harvey A; Bancke L; Feuerstadt P
    Open Forum Infect Dis; 2023 Jan; 10(1):ofac703. PubMed ID: 36686631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
    Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
    Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the gut microbiome in colonization resistance and recurrent
    Seekatz AM; Safdar N; Khanna S
    Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
    Berry P; Khanna S
    BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.
    Orenstein R; Dubberke E; Hardi R; Ray A; Mullane K; Pardi DS; Ramesh MS;
    Clin Infect Dis; 2016 Mar; 62(5):596-602. PubMed ID: 26565008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
    Louie T; Golan Y; Khanna S; Bobilev D; Erpelding N; Fratazzi C; Carini M; Menon R; Ruisi M; Norman JM; Faith JJ; Olle B; Li M; Silber JL; Pardi DS
    JAMA; 2023 Apr; 329(16):1356-1366. PubMed ID: 37060545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of fecal microbiota, live-jslm (REBYOTA
    Lee C; Louie T; Bancke L; Guthmueller B; Harvey A; Feuerstadt P; Khanna S; Orenstein R; Dubberke ER
    Therap Adv Gastroenterol; 2023; 16():17562848231174277. PubMed ID: 37333464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
    Sims MD; Khanna S; Feuerstadt P; Louie TJ; Kelly CR; Huang ES; Hohmann EL; Wang EEL; Oneto C; Cohen SH; Berenson CS; Korman L; Lee C; Lashner B; Kraft CS; Ramesh M; Silverman M; Pardi DS; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L;
    JAMA Netw Open; 2023 Feb; 6(2):e2255758. PubMed ID: 36780159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
    Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
    Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal microbiota transplantation in the treatment of recurrent intestinal Clostridioides difficile infection - a ten-year single-center experience.
    Pipek B; Valentová H; Fojtík P; Urban O
    Cas Lek Cesk; 2022; 161(3-4):126-130. PubMed ID: 36100450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
    Khanna S
    J Intern Med; 2021 Aug; 290(2):294-309. PubMed ID: 33856727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.